News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,486 Results
Type
Article (13753)
Company Profile (112)
Press Release (251621)
Section
Business (88681)
Career Advice (488)
Deals (15462)
Drug Delivery (64)
Drug Development (37418)
Employer Resources (51)
FDA (6392)
Job Trends (6341)
News (151897)
Policy (14146)
Tag
Academia (451)
Alliances (23261)
Alzheimer's disease (374)
Approvals (6395)
Artificial intelligence (62)
Bankruptcy (143)
Best Places to Work (4487)
Biotechnology (44)
Breast cancer (52)
Cancer (367)
Career advice (423)
Cell therapy (53)
Clinical research (31149)
Collaboration (165)
Compensation (64)
COVID-19 (758)
C-suite (53)
Data (393)
Diabetes (54)
Diagnostics (1295)
Drug pricing (57)
Earnings (31919)
Employer resources (47)
Events (37808)
Executive appointments (175)
FDA (6593)
Funding (110)
Gene therapy (61)
GLP-1 (301)
Government (1293)
Healthcare (3640)
Infectious disease (776)
Inflammatory bowel disease (48)
Interviews (61)
IPO (5916)
Job creations (2060)
Job search strategy (381)
Layoffs (171)
Legal (3429)
Lung cancer (57)
Manufacturing (100)
Medical device (1355)
Medtech (1357)
Mergers & acquisitions (9592)
Metabolic disorders (171)
Neuroscience (476)
NextGen Class of 2024 (1632)
Non-profit (617)
Northern California (487)
Obesity (103)
Opinion (110)
Patents (56)
People (28620)
Pharmaceutical (65)
Phase I (8145)
Phase II (13179)
Phase III (11809)
Pipeline (196)
Policy (45)
Postmarket research (1420)
Preclinical (3269)
Radiopharmaceuticals (117)
Rare diseases (94)
Real estate (2647)
Regulatory (9949)
Research institute (577)
Resumes & cover letters (58)
Southern California (464)
Startups (1633)
United States (4540)
Vaccines (118)
Weight loss (78)
Date
Today (3)
Last 7 days (129)
Last 30 days (1161)
Last 365 days (13089)
2024 (12191)
2023 (14682)
2022 (20013)
2021 (20459)
2020 (19408)
2019 (15162)
2018 (11940)
2017 (14132)
2016 (13338)
2015 (15736)
2014 (12563)
2013 (10669)
2012 (11475)
2011 (12009)
2010 (10961)
Location
Africa (315)
Arizona (44)
Asia (19995)
Australia (2590)
California (1097)
Canada (632)
China (126)
Colorado (45)
Connecticut (43)
Europe (39221)
Florida (157)
Illinois (117)
Indiana (87)
Japan (45)
Kansas (51)
Maryland (170)
Massachusetts (935)
Minnesota (59)
New Jersey (453)
New York (294)
North Carolina (284)
Northern California (487)
Pennsylvania (292)
South America (501)
Southern California (464)
Texas (149)
Virginia (41)
Washington State (75)
265,486 Results for "lb pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LB Pharmaceuticals Names Heather Turner as CEO to Lead its Development of Transformative Advances in Schizophrenia Treatment
November 19, 2024
·
4 min read
Press Releases
Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007
November 27, 2024
·
4 min read
Drug Development
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Recognition of Colon Cancer Cells by the Immune System
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced online publication of new pre-clinical data in the journal EMBO Reports, showing that its lead compound, LB-100, can turn immunologically “cold” tumors “hot,” potentially enhancing the benefit of immunotherapy.
June 6, 2024
·
4 min read
Drug Development
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
CervoMed Inc., a clinical stage company focused on developing treatments for age-related neurologic disorders, announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies.
June 11, 2024
·
5 min read
Biotech Beach
LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immunotherapy Cancer Treatments
LIXTE Biotechnology Holdings, Inc . today provided an update on the Company’s progress with its proprietary compound, LB-100.
March 21, 2024
·
5 min read
FDA
ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)
September 9, 2024
·
6 min read
Press Releases
CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)
October 15, 2024
·
6 min read
Drug Development
Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity
July 23, 2024
·
8 min read
Drug Development
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) today announced it has entered into a global licensing agreement with LG Chem, Ltd. (“LG Chem”), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.
January 4, 2024
·
12 min read
Biotech Beach
New Scientific Publication Shows LB-100, Lixte’s Lead Clinical Compound, Can Force Cancer Cells to Give Up Their Cancer-Causing Properties
LIXTE Biotechnology Holdings, Inc. announced publication of pre-clinical data in the online journal, Cancer Discovery, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” The finding opens a potentially new treatment strategy in addition to LIXTE’s current three clinical trials.
March 27, 2024
·
4 min read
1 of 26,549
Next